Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04143802 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04143802 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT04143802, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For each participant, the study will last up to about 5 months and will include 16 visits to the study center.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
- DRUG LY3437943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04143802
The ClinicalTrials.gov registry entry for NCT04143802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04143802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04143802 about?
NCT04143802 is a clinical study titled "A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)". The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injection...
What is the current status of trial NCT04143802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-12-18. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT04143802?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG), LY3437943 (DRUG).
Who is sponsoring clinical trial NCT04143802?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.